Check patentability & draft patents in minutes with Patsnap Eureka AI!

Inositol phosphate compounds for use in increasing tissular perfusion

A technology of compounds and compositions applied in the field of phosphoinositide compounds used to increase tissue perfusion, which can solve problems such as disappointing results and increasing the risk of adverse reactions

Pending Publication Date: 2021-09-07
SANIFIT THERAPEUTICS SA
View PDF41 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Cilostazol interacts with drugs such as cinacalcet, clopidogrel, and ibandronate regularly prescribed to patients with renal impairment or cardiovascular disease, increasing the risk of risk of adverse drug reactions
[0011] In conclusion, medical therapies for symptom relief are limited, and surgical or endovascular interventions are useful in some individuals, but long-term results are often disappointing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inositol phosphate compounds for use in increasing tissular perfusion
  • Inositol phosphate compounds for use in increasing tissular perfusion
  • Inositol phosphate compounds for use in increasing tissular perfusion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach 1

[0209] Embodiment 1. A compound of general formula I, or a pharmaceutically acceptable salt thereof, for use in increasing tissue perfusion and / or oxygenation in a subject in need thereof

[0210]

[0211] Among them, R 1 , R 3 , R 5 , R 7 , R 9 and R 11 Atom groups independently selected from OH, formulas II, III, IV, V, VI and VII:

[0212]

[0213] where: n is an integer in the range of 2 to 200, and R 13 selected from H, methyl, ethyl and C 3 -C 10 alkyl;

[0214] requirement is:

[0215] R 1 , R 3 , R 5 , R 7 , R 9 and R 11 At least one of is selected from the atomic groups of formula II, III and IV, and

[0216] R 1 , R 3 , R 5 , R 7 , R 9 and R 11 Zero, one, two or three of are selected from the atomic groups of formulas V, VI and VII.

Embodiment approach 2

[0217] Embodiment 2. A compound for use according to embodiment 1 for the treatment or prevention of peripheral arterial disease.

Embodiment approach 3

[0218] Embodiment 3. A compound for use according to any one of the preceding embodiments for the treatment or prevention of critical limb ischemia.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molar massaaaaaaaaaa
Login to View More

Abstract

The present invention relates to inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, for use in increasing tissular perfusion and / or oxygenation in a subject in need thereof, in particular peripheral arterial disease. The present invention also relates to pharmaceutical compositions comprising said inositol phosphates, analogs, derivatives and pharmaceutically acceptable salts thereof, and their use in increasing tissular perfusion and / or oxygenation and for treating and preventing peripheral arterial disease.

Description

[0001] This application claims the benefit of priority to applications EP19382061.0 filed on January 30, 2019 and US62 / 913,259 filed on October 10, 2019. technical field [0002] The present invention relates to the use of phosphoinositides (IP), analogs and derivatives thereof for increasing tissue perfusion and / or oxygenation. The invention also relates to pharmaceutical compositions comprising said IP, analogs and derivatives thereof and their use in animal and human health. Background technique [0003] Peripheral arterial disease (PAD) is a common condition characterized by narrowing and / or blockage of arteries of the lower extremities leading to decreased muscle perfusion and oxygenation. PAD is a major public health problem and poses a high risk of long-term suffering. PAD increases the risk of tissue death (gangrene), amputation, and premature death. [0004] PAD is the result of lower extremity ischemia. The main reason is atherosclerosis. In its mild form, PAD ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/6615A61P9/10A61P13/12
CPCA61P9/10A61P13/12C07F9/117A61K31/6615
Inventor M·F·巴西西C·萨尔塞多·罗卡J·佩雷罗·贝斯塔德M·D·费勒·瑞尼斯M·D·M·佩雷斯·费勒
Owner SANIFIT THERAPEUTICS SA
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com